When cell-associated myeloid markers were considered as biomarkers to differentiate HD from glioma patients, levels of CD15+ cells, MDSC1, and MDSC3 emerged as independent factors predicting the presence of disease (Table 2), with an overall accuracy of 87.1%. The gene discussed is FUT4; the disease is central nervous system cancer.